18 F-FDG PET/CT as an indicator of survival in Ewing sarcoma of bone

Usama Salem, Behrang Amini, Hubert H. Chuang, Najat C. Daw, Wei Wei, Tamara Miner Haygood, John E. Madewell, Colleen M. Costelloe

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: The existing literature of 18 F-FDG PET/CT in Ewing sarcoma investigates mixed populations of patients with both soft tissue and bone primary tumors. The aim of our study was to evaluate whether the maximum standardized uptake value (SUVmax) obtained with 18F-FDG PET/CT before and after induction chemotherapy can be used as an indicator of survival in patients with Ewing sarcoma originating exclusively in the skeleton. Materials and Methods: A retrospective database search from 2004-2011 identified 28 patients who underwent 18 F-FDG PET/CT before (SUV1, n= 28) and after (SUV2, n=23) induction chemotherapy. Mean follow up was 3.3 years and median follow up for survivors was 6.3 years (range: 2.6-9.8 years). Multivariate and univariate Cox proportional hazard model was used to assess for correlation of SUV1, SUV2, and the change in SUVmax with overall survival (OS) and progression-free survival (PFS). Results: Mean SUVmax was 10.74 before (SUV1) and after 4.11 (SUV2) induction chemotherapy. High SUV1 (HR = 1.05, 95% CI: 1.0-1.1, P = 0.01) and SUV2 (HR =1.2, 95% CI: 1.0-1.4, P = 0.01) were associated with worse OS. A cut off point of 11.6 was identified for SUV1. SUV1 higher than 11.6 had significantly worse OS (HR = 5.71, 95% CI: 1.85 – 17.61, P = 0.003) and PFS (HR = 3.16, 95% CI: 1.13 – 8.79, P = 0.03, P < 0.05 is significant). Conclusion: 18F-FDG PET/CT can be used as a prognostic indicator for survival in primary Ewing sarcoma of bone.

Original languageEnglish (US)
Pages (from-to)2892-2898
Number of pages7
JournalJournal of Cancer
Volume8
Issue number15
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Ewing's Sarcoma
Induction Chemotherapy
Bone and Bones
Survival
Fluorodeoxyglucose F18
Disease-Free Survival
Proportional Hazards Models
Skeleton
Survivors
Databases
Population
Neoplasms

Keywords

  • Ewing sarcoma
  • FDG PET/CT
  • Overall survival
  • Progression free survival
  • SUV

ASJC Scopus subject areas

  • Oncology

Cite this

Salem, U., Amini, B., Chuang, H. H., Daw, N. C., Wei, W., Haygood, T. M., ... Costelloe, C. M. (2017). 18 F-FDG PET/CT as an indicator of survival in Ewing sarcoma of bone. Journal of Cancer, 8(15), 2892-2898. https://doi.org/10.7150/jca.20077

18 F-FDG PET/CT as an indicator of survival in Ewing sarcoma of bone. / Salem, Usama; Amini, Behrang; Chuang, Hubert H.; Daw, Najat C.; Wei, Wei; Haygood, Tamara Miner; Madewell, John E.; Costelloe, Colleen M.

In: Journal of Cancer, Vol. 8, No. 15, 01.01.2017, p. 2892-2898.

Research output: Contribution to journalArticle

Salem, U, Amini, B, Chuang, HH, Daw, NC, Wei, W, Haygood, TM, Madewell, JE & Costelloe, CM 2017, '18 F-FDG PET/CT as an indicator of survival in Ewing sarcoma of bone', Journal of Cancer, vol. 8, no. 15, pp. 2892-2898. https://doi.org/10.7150/jca.20077
Salem U, Amini B, Chuang HH, Daw NC, Wei W, Haygood TM et al. 18 F-FDG PET/CT as an indicator of survival in Ewing sarcoma of bone. Journal of Cancer. 2017 Jan 1;8(15):2892-2898. https://doi.org/10.7150/jca.20077
Salem, Usama ; Amini, Behrang ; Chuang, Hubert H. ; Daw, Najat C. ; Wei, Wei ; Haygood, Tamara Miner ; Madewell, John E. ; Costelloe, Colleen M. / 18 F-FDG PET/CT as an indicator of survival in Ewing sarcoma of bone. In: Journal of Cancer. 2017 ; Vol. 8, No. 15. pp. 2892-2898.
@article{afed5355d50148e5851b9f6e0bc77768,
title = "18 F-FDG PET/CT as an indicator of survival in Ewing sarcoma of bone",
abstract = "Objective: The existing literature of 18 F-FDG PET/CT in Ewing sarcoma investigates mixed populations of patients with both soft tissue and bone primary tumors. The aim of our study was to evaluate whether the maximum standardized uptake value (SUVmax) obtained with 18F-FDG PET/CT before and after induction chemotherapy can be used as an indicator of survival in patients with Ewing sarcoma originating exclusively in the skeleton. Materials and Methods: A retrospective database search from 2004-2011 identified 28 patients who underwent 18 F-FDG PET/CT before (SUV1, n= 28) and after (SUV2, n=23) induction chemotherapy. Mean follow up was 3.3 years and median follow up for survivors was 6.3 years (range: 2.6-9.8 years). Multivariate and univariate Cox proportional hazard model was used to assess for correlation of SUV1, SUV2, and the change in SUVmax with overall survival (OS) and progression-free survival (PFS). Results: Mean SUVmax was 10.74 before (SUV1) and after 4.11 (SUV2) induction chemotherapy. High SUV1 (HR = 1.05, 95{\%} CI: 1.0-1.1, P = 0.01) and SUV2 (HR =1.2, 95{\%} CI: 1.0-1.4, P = 0.01) were associated with worse OS. A cut off point of 11.6 was identified for SUV1. SUV1 higher than 11.6 had significantly worse OS (HR = 5.71, 95{\%} CI: 1.85 – 17.61, P = 0.003) and PFS (HR = 3.16, 95{\%} CI: 1.13 – 8.79, P = 0.03, P < 0.05 is significant). Conclusion: 18F-FDG PET/CT can be used as a prognostic indicator for survival in primary Ewing sarcoma of bone.",
keywords = "Ewing sarcoma, FDG PET/CT, Overall survival, Progression free survival, SUV",
author = "Usama Salem and Behrang Amini and Chuang, {Hubert H.} and Daw, {Najat C.} and Wei Wei and Haygood, {Tamara Miner} and Madewell, {John E.} and Costelloe, {Colleen M.}",
year = "2017",
month = "1",
day = "1",
doi = "10.7150/jca.20077",
language = "English (US)",
volume = "8",
pages = "2892--2898",
journal = "Journal of Cancer",
issn = "1837-9664",
publisher = "Ivyspring International Publisher",
number = "15",

}

TY - JOUR

T1 - 18 F-FDG PET/CT as an indicator of survival in Ewing sarcoma of bone

AU - Salem, Usama

AU - Amini, Behrang

AU - Chuang, Hubert H.

AU - Daw, Najat C.

AU - Wei, Wei

AU - Haygood, Tamara Miner

AU - Madewell, John E.

AU - Costelloe, Colleen M.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective: The existing literature of 18 F-FDG PET/CT in Ewing sarcoma investigates mixed populations of patients with both soft tissue and bone primary tumors. The aim of our study was to evaluate whether the maximum standardized uptake value (SUVmax) obtained with 18F-FDG PET/CT before and after induction chemotherapy can be used as an indicator of survival in patients with Ewing sarcoma originating exclusively in the skeleton. Materials and Methods: A retrospective database search from 2004-2011 identified 28 patients who underwent 18 F-FDG PET/CT before (SUV1, n= 28) and after (SUV2, n=23) induction chemotherapy. Mean follow up was 3.3 years and median follow up for survivors was 6.3 years (range: 2.6-9.8 years). Multivariate and univariate Cox proportional hazard model was used to assess for correlation of SUV1, SUV2, and the change in SUVmax with overall survival (OS) and progression-free survival (PFS). Results: Mean SUVmax was 10.74 before (SUV1) and after 4.11 (SUV2) induction chemotherapy. High SUV1 (HR = 1.05, 95% CI: 1.0-1.1, P = 0.01) and SUV2 (HR =1.2, 95% CI: 1.0-1.4, P = 0.01) were associated with worse OS. A cut off point of 11.6 was identified for SUV1. SUV1 higher than 11.6 had significantly worse OS (HR = 5.71, 95% CI: 1.85 – 17.61, P = 0.003) and PFS (HR = 3.16, 95% CI: 1.13 – 8.79, P = 0.03, P < 0.05 is significant). Conclusion: 18F-FDG PET/CT can be used as a prognostic indicator for survival in primary Ewing sarcoma of bone.

AB - Objective: The existing literature of 18 F-FDG PET/CT in Ewing sarcoma investigates mixed populations of patients with both soft tissue and bone primary tumors. The aim of our study was to evaluate whether the maximum standardized uptake value (SUVmax) obtained with 18F-FDG PET/CT before and after induction chemotherapy can be used as an indicator of survival in patients with Ewing sarcoma originating exclusively in the skeleton. Materials and Methods: A retrospective database search from 2004-2011 identified 28 patients who underwent 18 F-FDG PET/CT before (SUV1, n= 28) and after (SUV2, n=23) induction chemotherapy. Mean follow up was 3.3 years and median follow up for survivors was 6.3 years (range: 2.6-9.8 years). Multivariate and univariate Cox proportional hazard model was used to assess for correlation of SUV1, SUV2, and the change in SUVmax with overall survival (OS) and progression-free survival (PFS). Results: Mean SUVmax was 10.74 before (SUV1) and after 4.11 (SUV2) induction chemotherapy. High SUV1 (HR = 1.05, 95% CI: 1.0-1.1, P = 0.01) and SUV2 (HR =1.2, 95% CI: 1.0-1.4, P = 0.01) were associated with worse OS. A cut off point of 11.6 was identified for SUV1. SUV1 higher than 11.6 had significantly worse OS (HR = 5.71, 95% CI: 1.85 – 17.61, P = 0.003) and PFS (HR = 3.16, 95% CI: 1.13 – 8.79, P = 0.03, P < 0.05 is significant). Conclusion: 18F-FDG PET/CT can be used as a prognostic indicator for survival in primary Ewing sarcoma of bone.

KW - Ewing sarcoma

KW - FDG PET/CT

KW - Overall survival

KW - Progression free survival

KW - SUV

UR - http://www.scopus.com/inward/record.url?scp=85028526042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028526042&partnerID=8YFLogxK

U2 - 10.7150/jca.20077

DO - 10.7150/jca.20077

M3 - Article

AN - SCOPUS:85028526042

VL - 8

SP - 2892

EP - 2898

JO - Journal of Cancer

JF - Journal of Cancer

SN - 1837-9664

IS - 15

ER -